Nextera
Nextera AS is a Norwegian biotech that develops TCR-Like antibodies and engineered T cell receptors via its proprietary NextCore phage display platform to target disease-specific pHLA complexes for cancer immunotherapy and autoimmune disease treatment.
- Company typePrivate
- Founded2009
- HeadquartersOslo, Norway
- Headcount11–50
- GTM typeB2B
- OfferingServices
What Nextera does
Nextera AS is a Norwegian private biotech company spun out in 2009 from the Centre of Excellence research environment at the University of Oslo and Oslo University Hospital. Co-founded by Geir Åge Løset (CEO/CSO) and Hans Ivar Robinson (Executive Chairman), the company develops TCR-Like antibodies and engineered T cell receptors that target disease-specific peptide-HLA (pHLA) complexes, expanding the addressable target space for antibody therapeutics into the intracellular antigen universe that has historically been accessible only to T cells.
Nextera's core offering is the NextCore drug-discovery platform, an integrated system built on proprietary pIX and pVII phage display technologies and comprising four functional modules: NextCore-Ab (TCR-Like antibody discovery), NextCore-TCR (TCR optimization for redirected cell therapy), and NextCore-HLAI/NextCore-HLAII (combinatorial pHLA class I and II libraries for target identification and profiling). The platform has produced preclinical candidates with picomolar affinities (Kd ~20 pM), including the lead antibody 3.C11 in celiac disease and pHLA-targeted T cell engagers in oncology. Scientific output has been validated through peer-reviewed publications in Science Immunology, PNAS and Gastroenterology, and the platform is protected by a granted US patent covering multivalent phage display systems.
The company's business model is sales-led and partnership-driven. Revenue (where generated) is sourced from licensing/royalty arrangements, collaborative drug discovery agreements, and platform access services negotiated with pharmaceutical and biotechnology partners. Active collaborations include Karolinska Institutet (rheumatoid arthritis tolerizing immunotherapy), Zelluna Immunotherapy (TCR-NK cell therapy), and multiple academic institutions. Nextera's go-to-market relies on scientific conference presence (PEGS Europe, BIO Europe, AET Europe) and direct enterprise outreach. To date, the company has been funded primarily through non-dilutive Norwegian Research Council grants (notably 15.7 MNOK in 2020 and an additional IPN award in November 2025) and early-stage support from Birk Venture in 2010, with no disclosed product revenue or commercial licensing transactions.
Nextera firmographics
Firmographics- Name
- Nextera
- Legal name
- Nextera AS
- Website
- https://nextera.no
- Company type
- Private
- Founded year
- 2009
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Nextera AS is a Norwegian biotech that develops TCR-Like antibodies and engineered T cell receptors via its proprietary NextCore phage display platform to target disease-specific pHLA complexes for cancer immunotherapy and autoimmune disease treatment.
- Ownership category
- akta.pro rank
Nextera industry classification
Industry- Product category
- Therapeutic Antibody Drug Discovery
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)
- akta.pro secondary industries
- CAR-T & TCR-T Therapies (HLAAABAC), Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)
Keywords
Where Nextera is headquartered
LocationHeadquarters
- HQ city
- Oslo
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
Nextera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales
Revenue model
- Partnership and Collaboration Revenue: Nextera discovers new targets and develops cognate drugs together with pharmaceutical partners. Revenue is generated through strategic partnerships, asset out-licensing, and collaborative development agreements.
- Platform Access and Research Services: The company offers access to its NextCore discovery platform and broader strategic partnerships for drug discovery services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Nextera product offering
Product offeringCore offering
Nextera develops TCR-Like antibody and TCR-based therapeutic candidates using its proprietary NextCore platform, which is built on a differentiated pIX phage display technology. The platform enables targeting of disease-specific pHLA complexes for cancer immunotherapy and autoimmune disease applications, generating antibody candidates with picomolar affinity and exquisite specificity through integrated modules including NextCore-Ab, NextCore-TCR, NextCore-HLAI, and NextCore-HLAII.
Product overview
Nextera is a drug and target discovery company offering the NextCore platform - an integrated drug discovery system comprising NextCore-Ab, NextCore-TCR, NextCore-HLAI, and NextCore-HLAII modules. The platform is built on unique pIX and pVII phage display technologies. The company accelerates a pipeline of TCR-Like antibody lead candidates and T cell engagers (TCEs) targeting disease-specific pHLA complexes for applications in cancer immunotherapy and autoimmune diseases. Nextera's strategy is to discover new targets and develop cognate drugs together with partners.
Differentiator
Problem solved
Functional benefit
Products and services
- NextCore Platform Integrated drug discovery platform enabling development of novel precision drug candidates targeting the intracellular universe of disease antigens through pHLA. It is built on Nextera's proprietary and differentiated pIX phage display technology and encompasses modules for antibody, TCR, and HLA class I/II library applications.
- TCR-Like Antibody Pipeline (Autoimmune Diseases) Pipeline of TCR-Like antibody lead candidates targeting disease-specific pHLA complexes for autoimmune indications including celiac disease and rheumatoid arthritis, supported by NextCore-Ab technology and partnerships with Karolinska Institutet and the Norwegian Research Council.
- TCR-Like Antibody Pipeline (Oncology) Pipeline of TCR-Like antibody lead candidates for cancer immunotherapy, leveraging the NextCore platform to develop high-affinity, disease-specific antibodies against intracellular cancer antigens.
- TCR-Like Antibody 3.C11 (Celiac Disease Lead Candidate) Lead TCR-Like antibody candidate targeting gluten peptide-MHC complexes in celiac disease with picomolar affinity, demonstrated to efficiently block activation and proliferation of gluten-responsive human CD4+ T cells in vitro and in TCR/HLA-DQ2.5 transgenic mice.
- T Cell Engagers (TCEs) TCR-Like antibody candidates reformatted as T cell engagers, demonstrating low picomolar cancer killing potency in liquid and solid cancer models including MAGE-A4 targeting candidates for oncology applications.
- Strategic Co-Development and Asset Out-Licensing Partnerships Partnership offerings where Nextera collaborates with pharmaceutical and biotech companies to discover new targets and co-develop cognate drug candidates using the NextCore platform, including asset out-licensing and platform access arrangements for immuno-oncology and autoimmunity programs.
Quantifiable outcome
- Generated one of the highest affinity fully human TCR-Like antibodies reported to date (Kd ~20 pM)
- +1 more outcomes
Companies that use Nextera
Customer profileSegments2 records
Ideal customer profiles2 records
Nextera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Nextera partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and supporting.
- Karolinska InstitutetcoreNextera AS announced collaboration with Karolinska Institutet (Stockholm, Sweden) on joint development of next generation targeted tolerizing immunotherapy for Rheumatoid Arthritis treatment. The multi-year program leverages Nextera's unique NextCore platform combined with Karolinska's preclinical and clinical capabilities in RA. TCR-Like antibodies will selectively target RA-associated autoantigens on HLA class II molecules for disease-specific suppression of pathogenic T cells while preserving protective immunity.
- Oslo University Hospital / University of OslosupportingCollaboration with OUS/UiO researchers on combining NextCore platform with computational methods for developing high-affinity TCR-Like antibodies, achieving Kd ~20 pM affinity.
- Zelluna Immunotherapy AScoreStrategic collaboration on optimizing T cell receptors (TCRs) for implementation into Zelluna's off-the-shelf TCR-based Natural Killer (TCR-NK) cell approach for cancer treatment. Nextera's NextCore platform uniquely equipped to harness new generation of TCR targeting modules to maximize efficacy and safety of TCR-NK cell therapies.
- Johns Hopkins UniversitysupportingCollaboration on generating and characterizing extremely sensitive TCR-Like antibodies towards gluten T cell epitopes in celiac disease using NextCore-Ab technology. Published in Science Immunology.
- Monash UniversitysupportingInternational collaboration partner in celiac disease research alongside Johns Hopkins University and Oslo University Hospital, contributing to TCR-Like antibody characterization study published in Science Immunology.
Scale indicators1 record
Recent moves7 records
Expansion highlights5 records
Nextera competitors and assessment
Company assessmentDirect peers
- Immunocore: UK/US TCR-based therapeutics company; founder Dr. Bent Jakobsen is on Nextera's board. Both companies focus on TCR-based immunotherapies targeting pHLA, making Immunocore the most direct peer in the TCR therapeutics category.
- Adaptimmune Therapeutics: Clinical-stage TCR-T cell therapy company (afami-cel approved). Like Nextera, Adaptimmune's lineage traces to Bent Jakobsen and targets pHLA complexes via engineered TCRs, with overlapping pipeline in solid tumor TCR therapy.
- Zelluna Immunotherapy: Norwegian biotech developing off-the-shelf TCR-NK cell therapies for cancer. Zelluna is an active Nextera partner receiving NextCore-optimized TCRs for redirected cell therapy, and operates in the same TCR/cell-therapy category.
- Eureka Therapeutics: US biotech pioneering TCR-Like antibody discovery against intracellular cancer antigens presented on pHLA. Closest direct comparator to Nextera's NextCore-Ab TCR-Like antibody pipeline and shares the same pHLA-targeting value proposition.
- Medigene: German immunotherapy company developing TCR-based therapies (including TCR-T cells and TCR-engineered T cells) for cancer. Overlapping in TCR technology platform and pHLA targeting with Nextera's NextCore-TCR franchise.
- BioInvent: Swedish clinical-stage biotech with antibody discovery capabilities using phage display and n-CoDeR library. BioInvent is highly comparable to Nextera on antibody/phage display technology, geographic base (Nordics), and cancer focus; BioInvent's CEO Martin Welschof also sits on Nextera's board.
- Maverick Therapeutics: US biotech (acquired by Takeda) developing T cell engagers (TCEs) and TCR-based bispecifics for cancer. Direct overlap with Nextera's TCE pipeline targeting pHLA cancer antigens (e.g., MAGE-A4).
- Polaris Pharmaceuticals: Biotech developing antibody-based therapeutics targeting pHLA complexes for cancer. Direct competitor to Nextera in the pHLA-targeting antibody space with overlap in TCR-Like antibody value proposition.
- TCR² Therapeutics: Clinical-stage cell therapy company developing novel T cell receptor fusion construct (TRuC) therapies. Comparable to Nextera in leveraging engineered TCR biology for cancer cell therapy, with adjacent technology overlap.
Broad incumbents
- Neogene Therapeutics: Acquired by AstraZeneca, Neogene is a TCR cell therapy platform company targeting neoantigens in solid tumors. Larger player with overlapping TCR-discovery capabilities; operates as a broad incumbent in Nextera's target category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Nextera social profiles
Digital presenceNextera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Nextera leadership team
Management profileNumber of profiles
Profiles11 records
Nextera funding detail
Funding detailFunding overview
Funding rounds1 record
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Nextera M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Nextera
What does Nextera do?
Nextera develops TCR-Like antibody and TCR-based therapeutic candidates using its proprietary NextCore platform, which is built on a differentiated pIX phage display technology. The platform enables targeting of disease-specific pHLA complexes for cancer immunotherapy and autoimmune disease applications, generating antibody candidates with picomolar affinity and exquisite specificity through integrated modules including NextCore-Ab, NextCore-TCR, NextCore-HLAI, and NextCore-HLAII.
Is Nextera a public or private company?
Nextera is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Nextera founded?
Nextera was founded in 2009. It employs 11 to 50 people.
Where is Nextera based?
Nextera is headquartered in Oslo, Norway, in the Europe region.
How does Nextera make money?
Two revenue lines are on record. Partnership and Collaboration Revenue is the primary driver. The others are platform Access and Research Services.
Who are Nextera's main competitors?
Direct peers on record are Immunocore, Adaptimmune Therapeutics, Zelluna Immunotherapy, Eureka Therapeutics, Medigene, BioInvent, Maverick Therapeutics, Polaris Pharmaceuticals and TCR² Therapeutics. Neogene Therapeutics is listed as a broad incumbent.
Does Nextera have an API?
No public API is recorded for Nextera.
What industry is Nextera in?
Nextera's product category is Therapeutic Antibody Drug Discovery. Its primary akta.pro industry code is HLAAAIAB, Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering), with a secondary code of HLAAABAC, CAR-T & TCR-T Therapies. Its NAICS code is 325412 and its SIC code is 2834.